A Phase 4 clinical trial update involving lixisenatide was recorded on June 22, 2026. The study, registered as NCT07274644, is titled "Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease."
The trial is listed as Phase 4 and its current status is active, not recruiting. This means enrollment for new participants is not currently open, while the study continues with participants already enrolled.
The trial is designed to compare iGlarLixi, a combination product containing lixisenatide, against iGlar in patients who have both type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. The stated focus of the comparison is liver fat content.
No results have been posted for this trial as part of this update. The information available reflects only the trial's registration details, phase, and recruitment status as of the listed date. No outcome data, efficacy claims, or safety findings are included in this update.
Readers can consult the compound overview for additional background on lixisenatide.